On CTMX's fourth-quarter 2024 earnings call, investors can expect updates regarding the developmental programs for its clinical-stage candidates.

Bio-Techne Corporation TECH recently announced Asuragen’s — a Bio-Techne brand —partnership with Oxford Nanopore Technologies to launch the AmplideX Nanopore Carrier Plus Kit. The research-use-only ...

Stoboclo, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Osenvelt, a ...

Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic ...

New indication for Tevimbra in combination with platinum-containing chemotherapy as a first-line treatment addresses an unmet ...

Clarity Pharmaceuticals will move to the next stage of its phase II trial to test its isotope-based therapy on prostate ...

Earlier this month, a fan named Emily Powell-Heaton, who is currently battling stage 4 metastatic breast cancer, took to X to ...

Here's what Dr Sinicrope said to see a healthcare provider if you experience any of the following symptoms of early-onset ...

The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for ...

In patients with advanced melanoma, nivolumab/relatlimab combination therapy shows a cutaneous irAEs prevalence of 21.5%, ...

BALVERSA (erdafitinib) has strong market potential in the FGFR-altered urothelial carcinoma space, particularly as a targeted therapy for patients wi ...

FY 2024 revenue of $228.4 million, in-line with company guidance <li /> Commercial Cell & Gene Therapy revenue rose to $26 million in FY ...